# Faron Pharmaceuticals

Source: https://onco.cc/companies/faron-pharmaceuticals/  
OnCo record `faron-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Faron Pharmaceuticals is a Finnish biotech whose antibody bexmarilimab re-programmes immunosuppressive macrophages, with early activity in myelodysplastic syndromes and leukaemia.

## Summary

Faron Pharmaceuticals, based in Turku and listed in London and Helsinki, develops immunotherapies that act on the myeloid arm of the immune system. Its lead candidate, bexmarilimab (FP-1305), binds Clever-1 on tumour-associated macrophages and converts them from an immunosuppressive to an immune-activating state. The BEXMAB study combines it with azacitidine in myelodysplastic syndromes and acute myeloid leukaemia; earlier MATINS trials tested it in solid tumours.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Faron; AIM:FARN
- Tags: drug-maker
- HQ: Turku
- Type: biotech
- Website: https://www.faron.com/
- Ticker: AIM:FARN

## Sources

- Official website: https://www.faron.com/

## Connected records

- drugs: [Bexmarilimab](https://onco.cc/drugs/bexmarilimab/)

---
JSON: https://onco.cc/api/v1/entities/faron-pharmaceuticals.json